FDA Adverse Event Injury Summary report: N

OMNIGUIDE FIBER

MDR report key: 7117438 · Received December 14, 2017

Report

Report Number
3005350457-2017-00001
Event Type
Injury
Date Received
December 14, 2017
Date of Event
November 10, 2017
Report Date
December 13, 2017
Manufacturer
OMNIGUIDE, INC
Product Code
GEX
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CO, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

AN ADVERSE EVENT WAS REPORTED BY A (B)(6) TECHNICIAN ON AN OTO-S FIBER (GEN1 LASER) ON (B)(6) 2017. THE GAS SETTING WAS ACCIDENTLY SET AT 70 PSI INSTEAD OF 10 PSI (AS INDICATED IN THE PROCEDURAL SETTINGS GUIDE). SURGEON STATED THAT THE EXCESSIVE GAS FLOW CAUSED INNER EAR INFLAMMATION. THE PATIENT HAD TO EXTEND THE STAY IN THE HOSPITAL. SURGEON STATED THAT THE HEARING WAS GOOD BUT WAS TREATED WITH STEROIDS FOR DIZZINESS. SURGEON MENTIONED THAT THE CONDITION WILL RESOLVE COMPLETELY WITH TIME. THE PRODUCT WAS NOT SENT BACK FOR EVALUATION, NO FAILURE OF THE FIBER WAS REPORTED. THE LASER WAS INSPECTED AND A PREVENTIVE MAINTENANCE WAS CONDUCTED WHICH DID NOT REVEAL ANY FAILURES WITH THE LASER UNIT.

Description of Event or Problem · 1

AN ADVERSE EVENT WAS REPORTED BY A (B)(6) TECHNICIAN ON AN OTO-S FIBER (GEN1 LASER) ON (B)(6) 2017. THE GAS SETTING WAS ACCIDENTLY SET AT 70 PSI INSTEAD OF 10 PSI (AS INDICATED IN THE PROCEDURAL SETTINGS GUIDE). SURGEON STATED THAT THE EXCESSIVE GAS FLOW CAUSED INNER EAR INFLAMMATION. THE PATIENT HAD TO EXTEND THE STAY IN THE HOSPITAL. SURGEON STATED THAT THE HEARING WAS GOOD BUT WAS TREATED WITH STEROIDS FOR DIZZINESS. SURGEON MENTIONED THAT THE CONDITION WILL RESOLVE COMPLETELY WITH TIME. THE PRODUCT WAS NOT SENT BACK FOR EVALUATION, NO FAILURE OF THE FIBER WAS REPORTED. THE LASER WAS INSPECTED AND A PREVENTIVE MAINTENANCE WAS CONDUCTED WHICH DID NOT REVEAL ANY FAILURES WITH THE LASER UNIT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
895728 OMNIGUIDE FIBER OTOLOGY FIBER GEX OMNIGUIDE, INC

Patients

Seq Age Sex Outcome Treatment
1 40 YR Other